Biotech Values

[oc631]

If there really was something "minor" in the letter they got, TEVA would surely let the world know as that had been their strategy for the previous 6 months up until that deficiency. TEVA going completely mum speaks volumes IMO.

We wouldn't be revisiting this issue if the FDA sent Teva a deficiency letter as opposed to a minor deficiency letter. This one word is the primary reason MNTA trades at such a low multiple. If Teva is unable to salvage T-Enox (as some believe) the FDA should have sent Teva a deficiency letter which allows the petitioner to decide for themselves whether it's a major or minor issue. The investment community would then speculate from a position which is fair to all companies operating in the space.